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Abstract 
Background: Evidence exists that glutamine plays multiple roles in glucose metabolism, insulin sensitivity, and 
anti-inflammatory effects. This systematic review and meta-analysis of controlled trials aimed to assess the effect of 
glutamine supplementation on cardio-metabolic risk factors and inflammatory markers.
Methods: The processes of systematic reviews and meta-analyses were performed according to the PRISMA checklist. 
PubMed, Web of Sciences, Cochrane library, and Scopus databases were search for relevant studies without time or 
language restrictions up to December 30, 2020. All randomized clinical trials which assessed the effect of glutamine 
supplementation on “glycemic indices”, “level of triglyceride, “and “inflammatory markers” were included in the study. 
The effect of glutamine supplementation on cardio-metabolic risk factors and inflammatory markers was assessed 
using a standardized mean difference (SMD) and 95% confidence interval (CI). Heterogeneity between among studies 
was assessed using Cochran Q-statistic and I-square. Random/fixed-effects meta-analysis method was used to estimate 
the pooled SMD. The risk of bias for the included trials was evaluated using the Cochrane quality assessment tool.
Results: In total, 12 studies that assessed the effect of glutamine supplementation on cardio-metabolic risk factors 
were included in the study. Meta-analysis showed that glutamine supplementation significantly decreased signifi-
cantly serum levels of FPG [SMD: − 0.73, 95% CI − 1.35, − 0.11,  I2: 84.1%] and CRP [SMD: − 0.58, 95% CI − 0.1, − 0.17, 
 I2: 0%]. The effect of glutamine supplementation on other cardiometabolic risk factors was not statistically significant 
(P > 0.05).
Conclusion: Our findings showed that glutamine supplementation might have a positive effect on FPG and CRP; 
both of which are crucial as cardio-metabolic risk factors. However, supplementation had no significant effect on 
other cardio-metabolic risk factors.
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Introduction
Glutamine is the most abundant amino acid in the 
human body vital for one’s health and plays an impor-
tant role in boosting the immune system and carbo-
hydrate metabolism [1]. In clinical practice, it has 
been shown that the glutamine supplementation can 
improve glucose homeostasis and reduce the need for 
exogenous insulin in patients with critical conditions 
[2]. Blood glucose levels in patients receiving glutamine 
supplementation were lower than those in controls, and 
this treatment might also reduce insulin requirements 
[3].
Previous studies have shown that glutamine can 
attenuate cytokine release from LPS-stimulated human 
peripheral blood mononuclear cells, and it can have 
various protective effects against cellular injury [4, 5]. 
An in vitro study has demonstrated that glutamine can 
enhance glucose-stimulated insulin secretion, contrib-
uting to worsening insulin resistance of patients with 
multiple trauma [6]. The glutamine can reduce hyper-
glycemia by increasing insulin sensitivity and improv-
ing its signaling in peripheral tissues which directly 
stimulate insulin production by the pancreatic beta 
cells [7, 8]. Moreover, glutamine supplementation 
enhances protein synthesis in catabolic/hypercatabolic 
conditions [9] and attenuates catabolic responses [10]. 
The findings of some studies support the hypothesis 
that glutamine supplementation as a dietary strategy 
can be beneficial in glycemic control in patients with 
type 2 diabetes and may be effective in controlling the 
obesity and diabetes [11, 12]. On the other hand, the 
recent systematic review of the effect of glutamine sup-
plementation on the glycemic profile of type 2 diabetic 
patients showed that glutamine improved insulin pro-
duction; however, the results on other metabolic risk 
factors are controversial [13].
Some previous studies conducted human subjects 
showed the beneficial effects of glutamine enteral or 
parenteral supplementation on the intestinal integ-
rity, immune-based responses, and the improvement 
in inflammatory markers and antioxidant capacity in 
intensive care unit patients as compared with a stand-
ard total parenteral nutrition (TPN) [14–17]. Arecent 
systematic review found that the effect of glutamine 
supplementation on inflammatory markers is inconclu-
sive and controversial [13].
Given the multiple roles of glutamine in glucose 
metabolism, insulin sensitivity and its anti-inflamma-
tory, and lack of meta-analysis examining the pooled 
effect of glutamine supplementation on cardiometa-
bolic risk factors and inflammatory markers; there-
fore, the effects of glutamine supplementation on 
these factors remain to be elucidated. This systematic 
review and meta-analysis of randomized controlled tri-
als (RCTs) aimed to pool the effect of glutamine sup-
plementation on the cardiometabolic risk factors and 
inflammatory markers.
Methods
In this systematic review and meta-analysis, the probable 
effects of glutamine supplementation on cardiometabolic 
risk factors and inflammatory markers were assessed 
according to the “Preferred Reporting Items for System-
atic Reviews Meta-Analyses” (PRISMA) checklist.
Study selection
All randomized controlled trials (RCTs), parallel or cross-
over design study, in adults or children population with 
any health condition, were included in this systematic 
review. The included studies should have assessed any 
form of glutamine supplementation (oral/TPN)) com-
pared to placebo. Fasting plasma glucose (FPG), insu-
lin, homeostasis model of assessment-estimated insulin 
resistance (HOMA-IR), quantitative insulin sensitivity 
check index (QUIKI), triglyceride (TG) were the primary 
outcomes. The secondary outcomes were inflammatory 
markers, such as C-reactive protein (CRP), Interleukin 
6 (IL-6), Glutathione (GSH), Interleukin 1(IL-1), and 
Tumor necrosis factor alpha (TNF-α).
Search strategy
To access all available related evidence, the most compre-
hensive international databases of PubMed/MEDLINE, 
Web of Science, Cochrane Library, and Scopus were 
searched for targeted papers without the time and lan-
guage restrictions up to December 30, 2020. The search 
strategy was entering the terms of “glycemic indices”, 
“level of triglyceride”, “inflammatory markers,” and “glu-
tamine supplementation”, without the restriction of ages 
of participants and time of publication. Reference lists 
of review papers are assessed to find related data. Grey 
literature and key journals were searched for additional 
data (Table 1).
Inclusion and exclusion criteria
We included studies used glutamine as a single therapy 
or combination therapy. Duplicate and non-relevant 
publications were excluded. To assess the relevancy of 
Keywords: Glutamine, Cardiometabolic risk factors, Systematic review, Meta-analysis
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paper, three steps of refinements of titles, abstracts and 
the full texts were followed by two independent investi-
gators. Possible disagreements were resolved by the third 
investigator.
Data extraction
Two independent investigators evaluated the eligibility 
criteria. The data related to citation information, details 
of study design, year of publication, the dose of supple-
mentation, intervention group, control group, mean age 
of the participants, outcome, intervention duration, fol-
low up information, measurements and result and effect 
size were extracted by using a data extraction sheet.
Quality assessment
The risk of bias for the included studies was evaluated 
using the Cochrane quality assessment tool for ran-
domized trials [18]. Two independent investigators 
assessed the quality of studies using the following seven 
criteria: random sequence generation, allocation conceal-
ment, blinding of participants and personnel, blinding of 
outcome assessment, incomplete outcome data, selective 
reporting, and other bias sources. To evaluate the quality 
of studies, each study was allocated a label indicating that 
it was judged as low risk, high risk, or unknown risk of 
bias, respectively.
Data synthesis and statistical analysis
Glycemic indices
The effect of glutamine supplementation on cardiometa-
bolic risk factors and inflammatory markers was assessed 
using standardized mean difference (SMD) and 95% 
confidence interval (CI). The data expressed as median 
and range were converted to mean and SD by applying 
the Hozo formula [18] and then SMD was calculated. 
A random-effect model was used if the Q-statistic for 
heterogeneity was significant at the level of 0.1 [18]. In 
other cases, the fixed-effect model was used [20]. The 
degree of heterogeneity was quantified using  I2 statis-
tics, which estimated the total variation across stud-
ies due to heterogeneity [21].  I2 values of 25%, 50%, and 
75% were considered to correspond to low, medium, 
and high heterogeneity levels, respectively. A random-
effect meta-regression analysis explored possible sources 
of heterogeneity (such as quality assessment score, the 
duration of intervention, study subjects, mean age of 
participants, dose of glutamine supplementation and 
female ration). Egger’s test estimated publication bias, 
and results of Egger’s test were considered as statistically 
significant at 0.1. The statistical analysis was conducted 
using STATA version 11 [22]. P value ≤ 0.05 was consid-
ered as statistically significant.
Ethical considerations
The study protocol was approved by the ethical commit-
tee of NIMAD institute. All of the included studies would 
be cited in future relevant reports and publications.
Results
Results of the search and the characteristics of included 
studies
A flow chart showing the study selection process is 
shown in Fig. 1. A total of twelve studies were included 
in the final step of selection according to the inclusion/
Table 1 Search strategy for selected databases
Pubmed
(("glutamine supplementation "[Mesh] OR "lipid profile"[Mesh] OR"Glucose Homeostasis"[Mesh] OR "Metabolic Syndrome X"[Mesh] OR "cardiometa-
bolic Syndrome "[ Title/Abstract] OR "Insulin Resistance Syndrome"[ Title/Abstract]) OR "Metabolic X Syndrome "[ Title/Abstract] OR "Dysmetabolic 
Syndrome"[Title/Abstract] OR "Cardiovascular Syndromes, Metabolic"[Title/Abstract] OR "Diabetes Mellitus, Type 2"[Mesh] OR "obesity"[Mesh] OR " 
abdominal obesity"[Mesh] AND ("Se"[Mesh] OR "se"[Title/Abstract]))
Scopus
(( ( TITLE-ABS-KEY ( Se) OR TITLE-ABS-KEY ( "Se")) AND ( ( TITLE-ABS-KEY ( "Metabolic Syndrome") OR TITLE-ABS-KEY ( cardiometabolic) OR TITLE-ABS-
KEY ( " Cardiovascular Syndromes" OR TITLE-ABS-KEY ( "Diabetes Mellitus") OR TITLE-ABS-KEY ( "Type 2 Diabetes") OR TITLE-ABS-KEY ( cardiovascular) 
OR TITLE-ABS-KEY ( "Syndrome X") OR TITLE-ABS-KEY ( "Insulin Resistance ") OR ( TITLE-ABS-KEY ( "glucose homeostasis") OR TITLE-ABS-KEY ( "Homeo-
stasis of Glucose") OR TITLE-ABS-KEY ( "Lipid profile ") OR TITLE-ABS-KEY ( "lipid panel") OR TITLE-ABS-KEY ( "Lipid_profile") OR TITLE-ABS-KEY ( " 
glutamine supplementation ")
ISI/WOS
TOPIC: (Se) OR TOPIC: (se)
( TOPIC: ("Metabolic Syndrome ") OR TOPIC: ("Mets ") OR TOPIC: ("Dysmetabolic Syndrome")OR TOPIC: ("Cardiovascular Syndromes") OR TOPIC: ("Insulin 
Resistance Syndrome ")
OR TOPIC: ("Cardiometabolic")OR TOPIC: ("Diabetes Mellitus ")OR TOPIC: ("Type 2 Diabetes ")OR TOPIC: ("Syndrome X ")OR TOPIC: ("glucose homeostasis 
")OR TOPIC: ("Homeostasis of Glucose ")
OR TOPIC: ("Lipid profile ")OR TOPIC: ("lipid panel ")OR TOPIC: ("Lipid_profile ") OR TOPIC: ("Oxidative Stress ") OR TOPIC: ("glutamine supplementation ")
Timespan = All years AND
Indexes = SCI-EXPANDED, SSCI, CPCI-S, CPCI-SSH Timespan = All years
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exclusion criteria. The characteristics of included studies 
are shown in Table 2.
The meta-analysis included 12 RCTs published 
between 2002 and 2015. In all studies, a total of 205 
participants were randomly assigned to the interven-
tion group and 173 participants to the control group. 
The age range of the participants was 10–71  years. 
Eight RCT recruited both men and women [26–33]. 
Only female subjects were enrolled in one study [24] 
and only male participants were enrolled in the three 
studies [3, 23, 25]. Seven trials used glutamine as oral 
supplement [3, 23–25, 29, 30, 33] and 5 trials used glu-
tamine supplementation with parenteral way [26–28, 
30, 31]. The dosage of glutamine supplements ranged 
from 0.3 mg/kg/day [33] to 50 gr/day [29] and the inter-
vention periods ranged from 0.5 days [23] to 120 days 







Full-text arcles assessed for 
eligibility
(n=42)





Full texts excluded for reasons:
Populaon not of interest: 9
Outcome not of interest: 13
Intervenon not of interest: 9
























Fig. 1 Flow chart of the number of studies selected for the meta-analysis
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[25]. All studies were the double blind, placebo-con-
trolled trials.
Subjects with maxillofacial surgery [23], patients with 
obesity and overweight [24], patients with Duchene 
Muscular Dystrophy [25], multiple trauma patients [26], 
patients with colon cancer resection [27], type 2 diabe-
tes [29], patients with laparoscopic cholecystectomy [3], 
heart surgery patients [28], patients with SIRS & sep-
sis[32], patients under cardiopulmonary bypass[31], 
patients with acute pancreatitis[33] and patients with 
type 2 diabetes under coronary artery bypass surgery[30] 
were en enrolled in the studies. There are no studies that 
have evaluated the effect of glutamine supplementation 
on hypertension.
Glutamine supplementation and glycemic indices
From 12 studies, nine RCTs including 249 participants 
in the glutamine or placebo groups reported FPG and 7 
studies with 185 participants reported insulin as the out-
come at baseline and follow-up. Five studies with 118 
participants reported HOMA-IR, and 3 RCT with 129 
participants reported QUIKI.
Meta-analyses suggested that intake of glutamine com-
pared with placebo resulted in a statistically significant 
improvement in FPG [pooled standardized mean differ-
ence [(SMD): − 0.73, 95% CI (− 1.35, − 0.11)] with obvi-
ous heterogeneity (Q = 50.17; P = 0.0;  I2% = 78.4).
There were no significant improvements on glycemic 
indices such as Insulin, [(SMD): − 0.75, 95% CI (− 1.65, 
0.15)] with obvious heterogeneity (Q = 51.52; P = 0.0; 
 I2% = 88.4), HOMA-IR [(SMD): − 1.38, 95% CI (− 2.92, 
0.15)] with obvious heterogeneity (Q = 66.78; P = 0.0; 
 I2% = 94), QUIKI [(SMD): 0.241, 95% CI (− 0.13, 0.62)] 
with obvious heterogeneity (Q = 1.54; P = 0.46;  I2% = 0.0). 
Subgroup analysis based on rout of supplementation 
showed that glutamine significantly reduced FPG in oral 
supplementation of glutamine [(SMD): − 0.56, 95% CI 
(− 0.89, − 0.23)] while the studies which used glutamine 
supplementation in parenteral way didn’t show this effect 
on FPG [(SMD): − 0.16, 95% CI (− 0.48, 0.16)]. Also, in 
this analysis we observed that glutamine supplemen-
tation in parenteral way significantly reduced Insulin 
[(SMD): − 1.63, 95% CI (− 2.26, − 1.01)] and HOMA-IR 
[(SMD): − 5.21, 95% CI (− 6.58, − 3.92)]. No significant 
differences were found in subgroup analyzed based on 
rout of supplementation with respect to the effect of glu-
tamine on QUIKI (Table  3). Pooled effect of glutamine 
supplementation on glycemic indices based on the rout 
of supplementation is presented in Figs. 2, 3, 4, 5.
Glutamine supplementation and level of Triglyceride
Pooled effect size based on 3 studies, including 127 par-
ticipants, indicated that glutamine supplementation 
did not significantly reduce serum levels of TG [(SMD): 
− 0.11, 95% CI (− 0.46, 0.24)] without obvious heteroge-
neity (Q = 0.11; P = 0.95;  I2% = 0.0). Subgroup analyzed 
based on rout of supplementation didn’t show any differ-
ences in the effect of glutamine on TG (Fig. 6).
Glutamine supplementation and inflammatory markers
Pooling effect sizes from 4 publications, including 126 
participants, we found that glutamine supplementation 
had a significant effect on CRP [(SMD): − 0.58, 95% CI 
(− 0.1, − 0.17)] without obvious heterogeneity (Q = 0.06; 
P = 0.97;  I2% = 0.0) while there were no significant 
effects of glutamine supplementation on IL-6 [(SMD): 
0.24, 95% CI (− 0.16,0.64)] without obvious heterogene-
ity (Q = 3.05; P = 0.22;  I2% = 34.5), GSH [(SMD): − 0.06, 
95% CI (− 0.63,0.51)] without obvious heterogeneity 
(Q = 0.52; P = 0.47;  I2% = 0.0), IL-1 [(SMD): − 0.58, 95% 
CI (− 1.44,0.27)] with obvious heterogeneity (Q = 3.27; 
P = 0.07;  I2% = 69.5) and TNF-α [(SMD): 0.21, 95% CI 
(− 0.23,0.66)] without obvious heterogeneity (Q = 1.49; 
P = 0.22;  I2% = 33.0).
In subgroup analyzed based on the rout of supplemen-
tation, we observed that the oral glutamine supplemen-
tation significantly reduced IL-1 [(SMD): − 1.06, 95% CI 
(− 1.83, − 0.30)] and glutamine supplementation in a par-
enteral way reduced CRP [(SMD): − 0.06, 95% CI (− 1.17, 
0.025)] while this result dod not observe in orally glu-
tamine supplementation (Figs. 7, 8, 9, 10, 11).
Quality assessment
Based on the Cochrane quality assessment tool, 4 trials 
were classified as good quality and the rest of the stud-
ies were classified as fair and poor quality. Among the 12 
randomized controlled trials, the main issues were a high 
risk of bias due to lack of blinding of participants and 
study personnel and lack of blinding of outcome assess-
ment. Details of the risk of bias assessment for included 
trials are presented in Table 4.
Meta‑regression
The effect of influencing factors was analyzed using a ran-
dom-effect meta-regression. There was no effect of influ-
encing factors, such as duration, mean age, dose, the rout 
of administration, type of indices and female ration on 
the heterogeneity of glycemic indexes such as FPG, Insu-
lin, HOMA-IR, HBA1C, TG, and inflammatory markers 
such as CRP, IL-6, GSH, IL-1 and TNF-α (P > 0.05).
Publication bias
Publication bias was estimated by Egger’s test. The results 
of Egger’s test did not support the existence of publication 
bias by glutamine supplementation on Insulin (coeffi-
cient = − 5.53, P = 0.08), HOMA-IR (coefficient = − 6.78, 
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P = 0.11), QUIKI (coefficient = 2.48, P = 0.47), TG (coeffi-
cient = 0.008, P = 0.99) and inflammatory markers (coef-
ficient = − 0.88, P = 0.67).
The results of Egger’s test supported the existence of 
publication bias by glutamine supplementation on FPG 
(coefficient = − 4.60, standard error = 1.82, P = 0.04, 95% 
CI − 8.9, − 0.29). The funnel plot of standard error versus 
effect size (mean difference) was slightly asymmetric The 
trim-and-fill correction suggested three potentially miss-
ing studies on the left side of the funnel plot. Imputation 
for this potentially missing study yielded an effect size of 
− 1.08 (95% CI − 1.85, − 0.31).
Discussion
This is one of the first reviews summarizing randomized 
controlled trials (RCTs) that aimed to bring together the 
results of all eligible RCTs to gauge the influence of glu-
tamine supplementation on glucose, insulin metabolism, 
lipid profile, and inflammatory factors.
In this study as a whole, glutamine supplementation 
reduced FPG as compared with placebo. In an attempt 
to address the effect of the route of the supplementa-
tion, oral versus parenteral trials included in the system-
atic review, we performed subgroup analyses to examine 
the role of these factors. We observed a more significant 
reduction of FPG for oral GLN. Combining all studies, 
no significant effects of glutamine supplementation on 
the parameters of insulin, HOMA-IR, and QUIKI were 
observed. Including only studies with parenteral glu-
tamine supplementation revealed a significant effect of 
glutamine supplementation on insulin and HOMA-IR. 
We investigated the efficacy of glutamine therapy (oral 
and/or intravenous) in the inflammatory factors and 
found that both oral and intravenous glutamine supple-
mentation reduced hs-CRP. Parenteral glutamine sup-
plementation was more effective in improving hs-CRP 
levels, but neither route reduced other inflammatory 
factors.
Interestingly, the beneficial effect of GLN on IL-1 was 
greater in the oral use of supplementation than the par-
enteral glutamine supplementation. The main challenge 
of this systematic review was the heterogeneity between 
the studies with GLN supplementation in the dose of reg-
imens of glutamine, much broader populations includ-
ing non-critically ill patients (obesity, type 2 diabetes), 
or specific populations (acute pancreatitis, SIRS & sep-
sis or surgery) and methods of administration used in 
the included studies. Our present analysis could not find 
strong signals of publication bias effects on the insulin 
levels and insulin resistance, lipid profile, and inflamma-
tory factors except for FPG.
Until recently, hyperglycemia in patients without a 
history of diabetes mellitus has often been viewed as 
an adaptive phenomenon caused by increased levels of 
counter-regulatory hormones, cytokines, and insulin 
resistance during periods of stress and decreased periph-
eral glucose use of tissues, mainly skeletal muscle and 
enhanced glucose production [28]. It has been described 
as ‘‘stress’’ hyperglycemia, and appears to be a marker 
for severity of disease in critically ill patients [34], and 
is strongly associated with an increased risk of mortal-
ity and morbidity among such patients [35]. It can be 
assumed that glutamine promotes in incretin hormone 
glucagon-like protein-1 (GLP-1) secretion from intes-
tinal L-cells [16], and GLP-1 like the other incretins, is 
secreted from the gut in response to binding nutrients 
to the receptors and can stimulate insulin secretion [36]. 
The beneficial effects seem to be glucose-dependent insu-
lin secretion and insulin action, providing a mechanism 
for the effects of oral glutamine on glycemic control [37, 
38]. Independent of increasing insulin secretion, GLP-1 
activation can increase the gastric emptying time and is 
thought to be the main cause of reduced glycemia in the 
glutamine [39]. In our meta-analysis, data showed no rise 
in insulin levels with oral admiration of glutamine.
We did not observe a clear difference in insulin lev-
els or insulin sensitivity after glutamine administration. 
However, in the subgroup analysis, the effect of glu-
tamine administration on insulin sensitivity improve-
ment was seen in trials that glutamine delivered by the 
parenteral route. This may be due to the various methods 
of administration and delivery and different intervention 
population. It should be noted that only two ials involv-
ing glutamine by parental route were included in this 
subgroup analysis, and in both studies, the dipeptide of 
glutamine was used. Variations in supplementation pro-
tocol may be more important in determining the efficacy 
of glutamine supplementation than volunteers’ charac-
teristics. It is unclear whether the attenuation of insulin 
resistance effect of glutamine is partly due to alanine. 
Additionally, recent studies found that serum glutamine 
concentrations were closely related to insulin sensitivity 
in glutamine supplemented people; most likely due to the 
IV route of delivery much higher plasma glutamine con-
centrations may be achieved [40].
There are several plausible biological mechanisms by 
which glutamine may affect serum lipid profile. Glu-
tamine has been shown to increase the absorption 
of triacylglycerol in the intestine of rats [41]. On the 
other hand, glutamine reduces lipid absorption due to 
increased GLP-1 levels [42]. In our meta-analysis, only 
three trials involving glutamine effects on lipid profile 
have been identified. Despite its effect on absorption and 
GLP-1 levels, our data showed that glutamine had no 
effects on TG levels.
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Data from pre-clinical and clinical studies suggest that 
glutamine induces inflammation mechanism and oxi-
dative damage through heat shock protein 70 (HSP70) 
release [43, 44] and glutathione (GSH) pathway, a critical 
antioxidant [45, 46], respectively. The beneficial effects 
of glutamine during critical illness are mainly related to 
its anti-inflammatory property rather than antioxidant 
effects [17]. Four trials investigatng the effect of glu-
tamine on inflammatory factors met the full inclusion 
criteria. Our analysis found evidence of hs-CRP reduc-
tion by supplementation with glutamine. Subgroup anal-
yses found evidence of a hs-CRP reduction in patients 
Table 3 Meta-analysis of effect of glutamine supplementation on glycemic indices, triglyceride and inflammatory markers
*Statistically significant
PN: parenteral nutrition; FBS: fasting blood sugar; HOMA-IR: homeostasis model of assessment-estimated insulin resistance; QUIKI: quantitative insulin sensitivity 
check index; CRP: C-reactive protein; IL: Interleukin; GSH: Glutathione; TNF-α: Tumor necrosis factor alpha; HbA1c: hemoglobin A1c; TG: Triglycerides
No. of study Pooled SMD (95% CI) P value Heterogeneity assessment P for between 
subgroup 
heterogeneityI
2 Q test P value
FBS
Oral 5 − 0.56 (− 0.89,− 0.23)* 0.001 75.8 16.54 0.002 0.088
PN 4 − 0.16 (− 0.48,0.16) 0.33 90.2 30.72 < 0.001
Total 9 − 0.73 (− 1.35,− 0.11)* 0.02 84.1 50.17 < 0.001
Insulin
Oral 5 0.07 (-.25,0.39) 0.66 67.3 12.23 0.016 < 0.001
PN 2 − 1.63 (− 2.26,− 1.01)* < 0.001 94.0 16.71 < 0.001
Total 7 − 0.75 (− 1.65,0.15) 0.10 88.4 51.52 < 0.001
HOMA-IR
Oral 4 0.04 (− 0.3,0.39) 0.8 69.9 9.97 0.019 < 0.001
PN 1 − 5.21 (− 6.58,− 3.92)* < 0.001 – – –
Total 5 − 1.38 (− 2.92,0.15) 0.07 94 66.78 < 0.001
QUIKI
Oral 2 0.13 (− 0.34,0.6) 0.59 0.0 0.90 0.34 0.42
PN 1 0.45 (-.18,1.08) 0.16 – – –
Total 3 0.24 (− 0.13,0.62) 0.20 0.0 1.54 0.46
TG
Oral 2 − 0.16 (− 0.65,0.33) 0.52 0.0 0.02 0.89 –
PN 1 − 0.05 (− 0.54,0.43) – – – –
Total 3 − 0.11 (− 0.46,0.24) 0.54 0.0 0.11 0.94
CRP
Oral 2 − 0.57 (− 1.16,0.02 ) 0.058 0.0 0.05 0.82 < 0.001
PN 1 − 0.6 (− 1.17,− 0.025)* – – – –
Total 3 − 0.58 (− 0.1,− 0.17)* 0.005 0.0 0.06 0.97
IL-6
Oral 2 0.40 (− 0.17,0.98 ) 0.17 59.1 2.45 0.12 –
PN 1 0.084 (− 0.48,0.64) – – – –
Total 3 0.24 (− 0.16,0.64) 0.24 34.5 3.05 0.22
GSH
Oral 2 − 0.06 (− 0.63,0.51 ) 0.83 0 0.52 0.47 –
IL-1
Oral 1 − 1.06 (− 1.83,− 0.30)* – – – – –
PN 1 − 0.18 (− 0.75,0.38) – – – –
Total 2 − 0.58 (− 1.44,0.27) 0.18 69.5 3.27 0.07
TNF-α
Oral 1 0.57 (− 0.15,1.31 ) – – – – –
PN 1 0.0 (− 0.56,0.56 ) – – – –
Total 2 0.21 (− 0.23,0.66) 0.35 33.0 1.49 0.22
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with parenteral use of glutamine. In addition, we found a 
relationship between the effects of oral supplementation 
on IL-1 levels. However, findings of this meta-analysis did 
not show a statistically significant impact of glutamine 
supplementation on other selected pro-inflammatory 
cytokines (TNF-α and IL-6).
It is important to note that the controversial results 
may come from the variations in several factors and may 
affect the interpretation of glutamine’s role on metabolic 
factors [47]. Some of these differences may be attributed 
to variations in the option of glutamine delivery, includ-
ing oral and parenteral route; we showed that different 
outcomes might derived from the glutamine different 
administration route of delivery. Possibly, the results 
obtained from this study may be related to this phenom-
enon. This variation can, for example, affectplasma lev-
els of glutamine; however, both parenteral and enteral 
glutamine administration lead to significant increases in 
plasma glutamine concentration, the metabolic pathway 
of glutamine into citrulline and arginine is affected by the 
route of administration, and there is a greater increase in 
plasma arginine when is given parenterally [48]. Another 
example is variation in glutamine administration forms 
(free or dipeptide) in the different route of administra-
tion; Free Glutamine is not a component of parenteral 
amino acid solutions because of its poor aqueous solu-
bility and easily hydrolyzed to glutamic acid and NH4 
when compared to dipeptide form. The use of glutamine-
containing dipeptides such as the dipeptide L-alanyl-L-
glutamine is a good alternative and has more availability 
and beneficial effects than free amino acids an area of 
research that needs to be tested in human subjects [45, 
49]. Another important note is the wide range of clinical 
trials conducted on different doses of glutamine supple-
mentation (from fixed dose of 20–35 g/d to adjusted dose 
of < 0.1  g/kg body weight/d) [50] which did not reach 
consensus on the best supplementation regime to nor-
malize plasma glutamine concentration without increas-
ing glutamate levels. However, in a study conducted by 
Nageli et  al., a high-dose glutamine supplementation 
Heterogeneity between groups: p = 0.088
Overall  (I-squared = 84.1%, p = 0.000)
Lomivorotov
Singh 2015









































Fig. 2 Forest plot of randomized controlled trials investigating the effect of glutamine supplementation on levels of fasting plasma glucose
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(0.75 g/kg/d) is thought to lead to increase in glutamine 
pool without a sign of potential glutamate-mediated 
cerebral injury. Nowadays, glutamine deficiency is com-
monly defined by low plasma glutamine levels [51]. The 
debate continues as to what level of glutamine supple-
mentation is necessary to achieve optimal effects [52]. 
However, in part, all studies were not included in this 
meta-analysis,which had targeted patients with the low-
est circulating glutamine levels. Another possibility is 
that glutamine level is a consequence [38], rather than a 
cause of disease or disease precursor states; It has been 
shown that critical illnesses, such as trauma, burn and 
sepsis are associated with acutely both intramuscular and 
circulating glutamine depletion [53] On the other hand,, 
plasma glutamine may be increased in some of conditions 
such as hepatic failure and renal dysfunction [47].
Limitations
The limitations of our study need to be mentioned. The 
included studies were almost all single-center trials, and 
most were of small to moderate sample size; this has 
not been clarified and confirmed in properly powered 
trials. While some effects on metabolic and inflamma-
tory factors were detected, subgroup analysis was mainly 
explored, and the size of the observed effect was modest. 
The target population of included trials was relatively dif-
ferent, and we could not perform subgroup meta-analysis 
according to the study population. Therefore the find-
ings should be interpreted cautiously. Another limita-
tion is the small number of trials that have specifically 
targeted patients with low glutamine levels at baseline; 
such patients may be more likely to respond to glutamine 
interventions. Due to time constraints, this study does 
not have the protocol registered in the International Pro-
spective Register of Systematic Reviews.
Conclusion
In this meta-analysis, we found a beneficial effect in 
improving the clinical outcomes after glutamine sup-
plementation in various diseases. Our subgroup analysis 
comparing oral and parenteral routs of administration 
showed varied results; however, this characteristic mod-
ifing the treatment effects has not been sufficiently 
studied for glutamine. Future well-controlled and 
Heterogeneity between groups: p = 0.000
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Fig. 3 Forest plot of randomized controlled trials investigating the effect of glutamine supplementation on levels of insulin
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NOTE: Weights are from random effects analysis
























Fig. 4 Forest plot of randomized controlled trials investigating the effect of glutamine supplementation on levels of HOMA-IR
NOTE: Weights are from random effects analysis





























Fig. 5 Forest plot of randomized controlled trials investigating the effect of glutamine supplementation on levels of QUIKI
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Fig. 6 Forest plot of randomized controlled trials investigating the effect of glutamine supplementation on levels of triglyceride


















Fig. 7 Forest plot of randomized controlled trials investigating the effect of glutamine supplementation on levels of CRP
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Fig. 8 Forest plot of randomized controlled trials investigating the effect of glutamine supplementation on levels of IL-6















Fig. 9 Forest plot of randomized controlled trials investigating the effect of glutamine supplementation on levels of GSH
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Fig. 10 Forest plot of randomized controlled trials investigating the effect of glutamine supplementation on levels of TNF-α
NOTE: Weights are from random effects analysis















Fig. 11 Forest plot of randomized controlled trials investigating the effect of glutamine supplementation on levels of IL-1
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well-randomized trials are needed to investigate the 
routes of glutamine administration which have the great-
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